Genistein-loaded nanoparticles of star-shaped diblock copolymer mannitol-core PLGA–TPGS for the treatment of liver cancer

Wu, Bian; Liang, Yong; Tan, Yulin; Xie, Chao; Jin, Shangtai; Zhang, Mei; Liu, Xinkuang; Yang, Lei; Zhang, Fu-Jian; Liu, Liang; Cai, Shuyu; Huai, De; Zheng, Donghui; Zhang, Rongbo; Zhang, Chao; Chen, Ke; Tang, Xiaolong; Xuemei, Sui

doi:10.1016/j.msec.2015.10.087

Cited by 58 publications

(20 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Polymer nanoparticles (NPs), one of the most promising and ideal drug carriers, acts as a continuous, detoxified, controlled release and targeted drug delivery system to significantly improve drug treatment and reduce toxic side effects [14,15]. Polymer nanocarriers with a diameter of 80-200 nm can avoid rapid renal clearance and recognition of the reticuloendothelial system (RES) in the liver, spleen, and lung; moreover, the 100-180-nm carrier has enhanced permeability and retention (EPR).…”

Section: Introductionmentioning

confidence: 99%

“…Polymer nanocarriers with a diameter of 80-200 nm can avoid rapid renal clearance and recognition of the reticuloendothelial system (RES) in the liver, spleen, and lung; moreover, the 100-180-nm carrier has enhanced permeability and retention (EPR). Effects accumulate at the tumor site [15][16][17]. Therefore, the application of nanocarriers with a size of 100-150 nm will be very important in antitumor treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

RETRACTED ARTICLE: The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway

Tang

Xie

et al. 2020

Nanoscale Res Lett

Self Cite

View full text Add to dashboard Cite

Polymer materials encapsulating drugs have broad prospects for drug delivery. We evaluated the effectiveness of polyethylene glycol-poly (lactic-co-glycolic acid) (PLGA-PEG) encapsulation and release characteristics of PI3K/mTOR inhibitor NVP-BEZ235 (BEZ235). We proposed a strategy for targeting radiosensitization of liver cancer cells. The biocompatibility, cell interaction, and internalization of Glypican-3 (GPC3) antibody-modified, BEZ235-loaded PLGA-PEG nanoparticles (NP-BEZ235-Ab) in hepatoma cells in vitro were studied. Also, the cell killing effect of NP-BEZ235-Ab combined with γ-ray cell was evaluated. We used confocal microscopy to monitor nanoparticle-cell interactions and cellular uptake, conducted focus-formation experiments to analyze the synergistic biological effects of NP-BEZ235-Ab and priming, and studied synergy in liver cancer cells using molecular biological methods such as western blotting. We found that PLGA-PEG has good loading efficiency for BEZ235 and high selectivity to GPC3-positive HepG2 liver cancer cells, thus documenting that NP-BEZ235-Ab acts as a small-molecule drug delivery nanocarrier. At the nominal concentration, the NP-BEZ235-Ab nanoformulation synergistically kills liver cancer cells with significantly higher efficiency than does the free drug. Thus, NP-BEZ235-Ab is a potential radiosensitizer.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway

Tang

Xie

et al. 2020

Nanoscale Res Lett

Self Cite

View full text Add to dashboard Cite

show abstract

“…209,210 In recent years, a few nanoscale techniques have been implemented to overcome the toxicity and higher dosage effects, improving the oral delivery of genistein. [211][212][213] Genisteinloaded polymeric micelles showed a higher bioavailability for genistein through oral delivery, with a particle size of ~27.76 nm. The bioavailability of the genistein micelles was greatly improved through oral delivery, and it was most likely due to the higher solubility of the compound and improved permeability.…”

Section: Nano-genisteinmentioning

confidence: 99%

Phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus – current status

Ganesan¹,

Arulselvan²,

Choi³

2017

IJN

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) is a major chronic disease that is prevalent worldwide, and it is characterized by an increase in blood glucose, disturbances in the metabolism, and alteration in insulin secretion. Nowadays, food-based therapy has become an important treatment mode for type 2 diabetes, and phytobioactive compounds have gained an increasing amount of attention to this end because they have an effect on multiple biological functions, including the sustained secretion of insulin and regeneration of pancreatic islets cells. However, the poor solubility and lower permeability of these phyto products results in a loss of bioactivity during processing and oral delivery, leading to a significant reduction in the bioavailability of phytobioactive compounds to treat T2DM. Recently, nanotechnological systems have been developed for use as various types of carrier systems to improve the delivery of bioactive compounds and thus obtain a greater bioavailability. Furthermore, carrier systems in most nanodelivery systems are highly biocompatible, with nonimmunologic behavior, a high degree of biodegradability, and greater mucoadhesive strength. Therefore, this review focuses on the various types of nanodelivery systems that can be used for phytobioactive compounds in treating T2DM with greater antidiabetic effects. There is also additional focus on improving the effects of various phytobioactive compounds through nanotechnological delivery to ensure a highly efficient treatment of type 2 diabetes.

show abstract

“…The data also showed that the genistein loaded mannitol PLGA-TPGS nanoparticles have greater antitumor efficacy when compared to linear PLGA-TPGS nanoparticles and PLGA nanoparticles in vitro (concentration range 0.25 to 25 lg/mL) and in vivo (50 mg/kg, bw in via intra-tumoral on days 0, 4 and 8). Thus, the star-shaped copolymer mannitol with PLGA-TPGS could be used as a potential and favorable bioactive material for nanomedicine synthesis for liver cancer treatment [39]. Docetaxel (DTX)-loaded polydopamine nanoparticles DTX-loaded nano formulations was prepared using polydopamine as surface modifying agent.…”

Section: Antitumor Activity Of Epirubicin-loaded Polymeric Nanoparticmentioning

confidence: 99%

Nanomedicines: a theranostic approach for hepatocellular carcinoma

Usmani

Mishra

Ahmad

2017

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

The liver is an imperative organ of tremendous importance concerned with maintenance of metabolic functions and detoxification of exogenous and endogenous challenges like xenobiotics, viral infections and chronic alcoholism. Liver diseases particularly hepatitis B virus infections, liver cirrhosis and hepatocellular carcinoma continue to pose a significant health challenge worldwide due to the lack of therapeutic management options besides liver resection and transplantation. Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer mortality worldwide. HCC has a high mortality rate because of poor diagnosis. The majority of patients with liver cancer die within one year as a result of poor patient compliance. HCC is clinically treated by chemotherapy besides surgery. However, most anticancer drugs have high toxicity and low specificity, leading to systemic toxicity and severe side effects. To limit the severe side effects of cancer chemotherapy on normal tissues, tumor targeting drug delivery systems need to be explored, which provides the impetus to develop targeted therapies for achieving higher efficacy with minimal side effects. The nanostructures used as good drug carriers, possess advantages of good solubility including high drug encapsulation efficiency, high cellular uptake, further desirable pharmacokinetics and can preferentially accumulate at the tumor site through the enhanced permeability and retention (EPR) effect with the goal of minimizing toxic effects on healthy tissues while maintaining antitumor efficacy.

show abstract

Genistein-loaded nanoparticles of star-shaped diblock copolymer mannitol-core PLGA–TPGS for the treatment of liver cancer

Cited by 58 publications

References 38 publications

RETRACTED ARTICLE: The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway

RETRACTED ARTICLE: The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway

Phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus – current status

Nanomedicines: a theranostic approach for hepatocellular carcinoma

Contact Info

Product

Resources

About

Genistein-loaded nanoparticles of star-shaped diblock copolymer mannitol-core PLGA–TPGS for the treatment of liver cancer

Cited by 58 publications

References 38 publications

RETRACTED ARTICLE: The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway

RETRACTED ARTICLE: The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway

Phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus &ndash; current status

Nanomedicines: a theranostic approach for hepatocellular carcinoma

Contact Info

Product

Resources

About

Phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus – current status